Abstract
Context Estradiol is the primary female sex hormone and plays an important role for skeletal health in both sexes. Several enzymes are involved in estradiol metabolism but few genome-wide association studies (GWAS) have been performed to characterize the genetic contribution to variation in estrogen levels.
Objective Identify genetic loci affecting estradiol levels and estimate causal effect of estradiol on bone mineral density (BMD).
Design We performed GWAS for estradiol in males (N = 147,690) and females (N = 163,985) from UK Biobank (UKB). Estradiol was analyzed as a binary phenotype; above/below detection limit (175 pmol/L). We further estimated the causal effect of estradiol on BMD using Mendelian randomization.
Results We identified 14 independent loci associated (P<5×10−8) with estradiol levels in males, of which one (CYP3A7) was genome-wide and seven nominally (P<0.05) significant in females. In addition, one female specific locus was identified. Most loci contain functionally relevant genes that have not been discussed in relation to estradiol levels in previous GWAS. For example, SRD5A2, which encodes a steroid 5-alpha reductase that is involved in processing androgens, and UGT3A1 and UGT2B7 which encode enzymes likely to be involved in estradiol elimination. The allele that tags the O blood group, at the ABO locus, was associated with higher estradiol levels. We identified a causal effect of high estradiol levels on increased BMD in both males (P=1.58×10−11) and females (P=7.48×10−6).
Conclusion Our findings further support the importance of the body’s own estrogen to maintain skeletal health in males and in females.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The research was funded by the Swedish Research Council (Å.J), the cancer foundation (Å.J), the brain foundation (Å.J), the Å Wiberg (W.E.E), M Borgström (W.E.E), Hedströms, K och O F (W.E.E), A and M Rudbergs (W.E.E) foundations.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
UKB has an ethics permit from the National Research Ethics Committee (REC reference 11 / NW / 0382). Ethical approval for the analyses performed in this study has also been approved by the Swedish Ethical Review Authority (Dnr: 2020-04415).
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Grants/Fellowships supporting paper: The research was funded by the Swedish Research Council (Å.J), the cancer foundation (Å.J), the brain foundation (Å.J), the Å Wiberg (W.E.E), M Borgström (W.E.E), Hedströms, K och O F (W.E.E), A and M Rudbergs (W.E.E) foundations.
Disclosure summary: Nothing to declare
Data Availability
The data used for this study is available for bona fide researchers from the UK Biobank Resource (http://www.ukbiobank.ac.uk/about-biobank-uk/), and can be accessed by an application to the UK Biobank. GEFOS data included in this study can be downloaded from http://www.gefos.org.
